Publicaciones en colaboración con investigadores/as de University of Leicester (2)

2019

  1. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials

    Diabetes and Metabolism, Vol. 45, Núm. 5, pp. 409-418

2017

  1. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)

    Diabetes, Obesity and Metabolism, Vol. 19, Núm. 7, pp. 1024-1031